Amgen Inc.شراء
$AMGN A big week ahead for Amgen, now it's found a bottom.
Amgen will present data from its oncology pipeline at the 55th Annual Meeting of the American Society of Clinical Oncology that begins on May 31. This Could a hugely significant day for AMGN which is in need of some good news to reassure investors. They stock has been on a terrible run lately but it may now have found a bottom, ready to move higher as the entire sector sell-off has left these companies at very attractive P/E ratios, offering stability and cash generation at a time when tech is in the wars.
RECENT DEVELOPMENTS
Amgen (NASDAQ:AMGN) has made a cash offer of SEK 1,610 (US167M) for Copenhagen-based Nuevolution AB, a developer of small molecule therapeutics in inflammation, oncology and immuno-oncology utilizing its drug discovery platform called Chemetics.
AVERAGE ANALYSTS PRICE TARGET $206
AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT
12 BUY
1 OVERWEIGHT
1 2 HOLD
P/E RATIO 13.66
COMPANY PROFILE
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA.
AMGN which is in need of some good news to reassure investors. They stock has been on a terrible run lately but it may now have found a bottom, ready to move higher as the entire sector sell-off has left these companies at very attractive P/E ratios, offering stability and cash generation at a time when tech is in the wars. RECENT DEVELOPMENTS
Amgen (NASDAQ:AMGN) has made a cash offer of SEK 1,610 (US167M) for Copenhagen-based Nuevolution AB, a developer of small molecule therapeutics in inflammation, oncology and immuno-oncology utilizing its drug discovery platform called Chemetics.
AVERAGE ANALYSTS PRICE TARGET $206
AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT
12 BUY
1 OVERWEIGHT
1 2 HOLD
P/E RATIO 13.66
COMPANY PROFILE
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA.
إخلاء المسؤولية
لا يُقصد بالمعلومات والمنشورات أن تكون، أو تشكل، أي نصيحة مالية أو استثمارية أو تجارية أو أنواع أخرى من النصائح أو التوصيات المقدمة أو المعتمدة من TradingView. اقرأ المزيد في شروط الاستخدام.
إخلاء المسؤولية
لا يُقصد بالمعلومات والمنشورات أن تكون، أو تشكل، أي نصيحة مالية أو استثمارية أو تجارية أو أنواع أخرى من النصائح أو التوصيات المقدمة أو المعتمدة من TradingView. اقرأ المزيد في شروط الاستخدام.